et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol.
1999;19511- 518Link to Article
et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med.
1999;341801- 806Link to Article
et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med.
1996;100530- 536Link to Article
RL Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Int J Hematol.
1997;65193- 213Link to Article
RL The antiphospholipid thrombosis syndromes: fact, fiction, confusion and controversy. Am J Clin Pathol. 1993;100477- 480
M Epidemiology of the antiphospholipid syndrome. Asherson
YThe Antiphospholipid Syndrome. Boca Raton, Fla CRC Press1996;13- 28
WF Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost.
1992;18267- 274Link to Article
H Syndromes of thrombosis and hypercoagulability. Med Clin North Am.
1998;82409- 458Link to Article
TL Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med.
1997;127177- 185Link to Article
et al. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost.
1998;24367- 379Link to Article
B New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg 506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74139- 148
et al. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood. 1998;911135- 1139
et al. Factor V Cambridge: a new mutation (Arg 306 to Thr) associated with resistance to activated protein C. Blood. 1998;911140- 1144
et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost. 1999;81193- 197
et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy young men. N Engl J Med.
1995;332912- 917Link to Article
et al. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost. 1997;787- 12
et al. High risk of thrombosis in patients homozygous for factor V Leiden. Blood. 1995; Mar15 85
et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;922353- 2358
et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81198- 202
A Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med.
1999;130643- 650Link to Article
et al. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Am J Hematol.
1997;5559- 64Link to Article
et al. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood. 1997;891963- 1967
van der Meer
et al. The Leiden Thrombophilia Study. Thromb Haemost. 1997;78631- 635
et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet.
1995;345152- 155Link to Article
et al. High plasma concentrations of factor VIII:C is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;835- 9
et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997;77825- 828
et al. Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 2000;8310- 13
JP Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost. 1999;821024- 1027
AI The prethrombotic state in cancer. Semin Oncol. 1990;17147- 159
RL Hemostatic alterations in cancer patients. Cancer Metastasis Rev.
1992;11237- 248Link to Article
et al. Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients, part I: coagulation study. Am J Clin Pathol. 1979;7110- 16
W Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathologic, and therapeutic features. Medicine (Baltimore).
1977;561- 37Link to Article
EF Sticky platelet syndrome. Semin Thromb Hemost.
1999;25361- 365Link to Article
EF Ten years' experience with the "sticky platelet syndrome.". Clin Appl Thromb Hemost.
1995;166- 72Link to Article
et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;7387- 93
JH Clinical studies on protein C. Semin Thromb Hemost.
1984;10162- 166Link to Article
RM Congenital protein C deficiency and venous thromboembolism: a study of three Dutch families. N Engl J Med.
1983;309340- 344Link to Article
AW Hereditary protein C deficiency. Haemostasis. 1985;15
K Hypercoagulable states. Hoffman
SHematology: Basic Principles and Practice 2nd ed. Camden Town, London, England Churchill Livingstone Inc1995;1781- 1794
R Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost.
1999;25387- 406Link to Article
et al. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med.
1987;106677- 682Link to Article
M Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am.
1998;121141- 1166Link to Article
GM Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80874- 877
GM Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res.
1993;71337- 359Link to Article
PC Homocysteine, atherogenesis and thrombosis. Fibrinolysis.
1997;1177- 80Link to Article
IFW Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis.
1997;20307- 315Link to Article
et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb.
1994;14465- 470Link to Article
et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol.
1994;87106- 112Link to Article
K Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981;10369- 390
PA Familial thrombosis due to antithrombin III deficiency. Blood. 1974;43219- 231
J Laboratory investigation of hypercoagulability. Semin Thromb Hemost.
1998;24111- 126Link to Article
D Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol. 1991;2831- 38
EF Plasminogen abnormalities. Semin Thromb Hemost.
1983;950- 51Link to Article
CE Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after PTCA. Thromb Haemost. 1989;62772- 775
EA Disturbed fibrinolysis in patients with inflammatory bowel disease. Gut.
1989;30188- 194Link to Article
et al. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients–relationship with plasma insulin. Thromb Haemost. 1989;61370- 373
R Index of Variant Human Fibrinogens. Boca Raton, Fla CRC Press1994;
OD Thrombosis or myocardial infarction in congenital clotting factor abnormalities and thrombocytopenias: a report of 21 patients and a review of previously reported cases. Medicine (Baltimore).
1983;62248- 255Link to Article
et al. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol.
1998;1031045- 1050Link to Article
et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79706- 708
JP G20210A mutation in prothrombin gene and risk of MI, stroke, and venous thrombosis in a large cohort of US men. Circulation.
1999;99999- 1004Link to Article
et al. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol.
1997;98907- 909Link to Article
et al. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78990- 992
P Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost. 1999;81203- 207
et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost. 1998;80743- 748
et al. Hypercoagulable states in primary upper extremity DVT. Arch Intern Med.
2000;160382- 386Link to Article
et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med.
1999;340901- 907Link to Article
KA Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost. 1995;7494- 100